Humacyte Inc Total Liabilities
Humacyte Inc total liabilities. Based on the latest financial reports, Humacyte Inc (HUMA) has total liabilities worth $113.26 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Humacyte Inc (HUMA) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Humacyte Inc (2019–2025)
Total liabilities of Humacyte Inc from 2019 to 2025. This chart illustrates how Humacyte Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Humacyte Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Humacyte Inc Competitors by Total Liabilities
The table below lists competitors of Humacyte Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kewaunee Scientific Corporation
NASDAQ:KEQU
|
USA | $98.58 Million |
|
Samick Thk
KO:004380
|
Korea | ₩257.11 Billion |
|
Amotech Co. Ltd
KQ:052710
|
Korea | ₩175.85 Billion |
|
Hana Pharm Co Ltd
KO:293480
|
Korea | ₩114.94 Billion |
|
Yoosung T&S Co. Ltd
KQ:024800
|
Korea | ₩99.40 Billion |
|
Taeyang Metal Industrial Co Ltd
KO:004105
|
Korea | ₩443.01 Billion |
|
Accel Solutions Group Ltd
TA:ACCL
|
Israel | ILA292.30 Million |
|
Smartphoto Group NV
BR:SMAR
|
Belgium | €36.85 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Humacyte Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Humacyte Inc's balance sheet.
Liquidity & Leverage Metrics
Humacyte Inc Total Liabilities Ratios Explained
Humacyte Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 36.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Humacyte Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Humacyte Inc (2019–2025)
The table below shows the annual total liabilities of Humacyte Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $113.26 Million | -40.56% |
| 2024-12-31 | $190.54 Million | +66.15% |
| 2023-12-31 | $114.68 Million | +31.25% |
| 2022-12-31 | $87.37 Million | -46.84% |
| 2021-12-31 | $164.36 Million | +356.35% |
| 2020-12-31 | $36.02 Million | -1.30% |
| 2019-12-31 | $36.49 Million | -- |
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more